N6-methyladenosine (m 6 A) demethylase FTO is significantly upregulated in MPP + -stimulated SK-N-SH cells, which suppresses YTH domain family protein 2 (YTHDF2) expression, promotes m 6 A demethylation of BRCA1-associated protein 1 (BAP1) and enhances BAP1 expression, upregulates p53 expression, and inhibits SLC7A11 transcription, thereby increasing MDA, Fe 2+ , and 4-HNE levels and triggering neuronal ferroptosis
Bryce, as usual, great insights AND graphic representation
The reasons are simple - 1) Less price erosion than US generics many ROW markets operate on tender-based or branded-generic models with less competitive intensity 2) Higher entry barriers than domestic Indiarequires regulatory filings (EU GMP, WHO PQ, ANVISA), distribution infrastructure, and local market knowledge 3) Branded potential - unlike the US where generics are interchangeable, many ROW markets allow branded generics that can command premium pricing 4) Large unmet need - healthcare access in Africa, LatAm, and Southeast Asia is expanding, creating genuine volume growth (not just market share battles) Lets see who is doing well here - 13) Strides Pharma - The Ex-US Transformation Story + Controlled drug substances Strides transformation from a US-centric generics player to a diversified international formulator is one of the most underappreciated stories in Indian pharma

This isn't about which molecule is "better" it's about which supplement delivers more value for your specific goals
Front Immunol (2020) 11:172033